EXECUTIVE MANAGEMENT BIO
Felix A. de la Iglesia, M.D.
Chief Enterprise Officer
mobile: 734.330.9030
email: iglesia@mtrinstitute.com
Dr. de la Iglesia is Chief Enterprise Officer. Dr. de la Iglesia retired from Parke-Davis/Pfizer as
Vice President, Preclinical Worldwide Safety in 2000 after 34 years serving in several research and development management
positions. In 2001, he co-founded Cambridge Biotechnology Corporation, a biotechnology pharmaceutical startup in Cambridge,
England. In 2003, Dr. de la Iglesia co-founded QRxPharma Pty Ltd, a biopharmaceutical startup company in Brisbane, Australia
and served as Chief Scientific Officer and Vice President of Research and Development.
He is a Fellow of the Academy of
Toxicological Sciences and has authored numerous articles, book chapters, abstracts and books. His academic appointments
include Adjunct Professor of Pathology, School of Medicine and Adjunct Professor of Toxicology at the School of Public Health,
University of Michigan. He is Adjunct Professor in Microbial and Molecular Sciences at the University of Queensland in Brisbane,
Australia. Dr. de la Iglesia established FIP Consulting, a health sciences worldwide research and development consultancy,
providing services to pharmaceutical and biotechnology companies in the US, Canada, Europe and Japan.